8-K - Kiora Pharmaceuticals, Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Kiora Pharmaceuticals announced the resignation of Chief Development Officer Eric J. Daniels effective April 17, 2026, to pursue another opportunity, with the company initiating a search for his successor.

Key Takeaways

1Chief Development Officer Eric J. Daniels will resign effective April 17, 2026, to pursue another opportunity.

2The resignation did not result from any disagreement regarding the company's operations, policies, or practices.

3Kiora has initiated a search for Daniels' successor.

4The company states it remains focused on advancing its pipeline of treatments for retinal disease and maintaining momentum across its development programs.

5The ABACUS-2 Phase 2 clinical trial (KIO-301) received approval to enroll remaining patients in the 50µg dose cohort and clearance to initiate the 100µg dose cohort.

6All planned safety review checkpoints have been cleared in the KLARITY Phase 2 clinical trial (KIO-104), with patient enrollment ongoing.

Current Report Details

Event Type

Management Change

Regulation Fd

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

5.02

. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 1,

Management Change

7.01

. Regulation FD Disclosure. On April 2, 2026, the Company issued a press release announcing Mr. Daniel’s resignation. A copy of the press release is furnished a

Regulation Fd

9.01

. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number: 99.1 | Title: Press Release of Kiora Pharmaceuticals, Inc., dated as of April 2, 2026 Exhibit

Exhibits Only

Source Document

Executive & Director Changes

Eric J. Daniels, M.D., MBA

Chief Development Officer

Resignation

Effective: 2026-04-17

To pursue another opportunity

Exhibits (2)

8-K

99.1

EX-99.1